Safety and Efficacy of Saccharomyces boulardii for the management of Diarrhoea in Indian children

Main Article Content

Dr. Mayuresh Kiran Mr. Lalit Pawaskar


Objective: S. boulardii seem to be an assuring biotherapeutic agent for the amelioration of the course of diarrhoea in children when used therapeutically. S. boulardii mediates responses resembling the protective effects of the normal healthy gut flora. Our objective was to access the safety and efficacy of S. boulardii on childhood diarrhea.

Methodology: Total 210 patients were enrolled out of which 184 patients completed the study S. boulardii sachets (5 million CFU~282.5mg) were given to the patients enrolled in the study. Efficacy and safety assessment was made by quantitating the Frequency, Intensity and Consistency of stools.

Results: Stool frequency decreased from 9.005 to 2.7 at the end of 5 days. Severity scale was extrapolated which interestingly showed zero patients with severe diarrhoea. There was a reduction in the duration of diarrhoea along with stool consistency where in majority patients with watery stool came down to 2 from 136.

Conclusions: Saccharomyces boulardii is safe and efficacious in the treatment of diarrhoea in Indian children


Download data is not yet available.

Article Details

How to Cite
Kiran, D. M., & Pawaskar, M. L. (2018). Safety and Efficacy of Saccharomyces boulardii for the management of Diarrhoea in Indian children. International Journal of Scientific Research and Management, 6(01), MP-2018.
Medical Sciences and Pharmacy


1. Giannattasio A, Guarino A, Vecchio AL. Management of children with prolonged diarrhea. F1000Research. 2016;5.
2. Lee KJ. Pharmacologic agents for chronic diarrhea. Intestinal research. 2015 Oct 1;13(4):306-12.
3. Lakshminarayanan S, Jayalakshmy R. Diarrheal diseases among children in India: current scenario and future perspectives. Journal of natural science, biology, and medicine. 2015 Jan;6(1):24.
4. REHYDRATION O. Treatment of diarrheal disease.
5. Rao K, Young VB. Fecal microbiota transplantation for the management of Clostridium difficile infection. Infectious disease clinics of North America. 2015 Mar 31;29(1):109-22.
6. Verna EC, Lucak S. Use of probiotics in gastrointestinal disorders: what to recommend?. Therapeutic advances in gastroenterology. 2010 Sep;3(5):307-19.
7. Kechagia M, Basoulis D, Konstantopoulou S, Dimitriadi D, Gyftopoulou K, Skarmoutsou N, Fakiri EM. Health benefits of probiotics: a review. ISRN nutrition. 2013 Jan 2;2013.
8. Guandalini S. Probiotics for prevention and treatment of diarrhea. Journal of Clinical Gastroenterology. 2011 Nov 1;45:S149-53.
9. Stier H, Bischoff SC. Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. Clinical and experimental gastroenterology. 2016;9:269.
11. Johnston BC, Supina AL, Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. Canadian Medical Association Journal. 2006 Aug 15;175(4):377-83.
12. Dinleyici EC, Eren M, Ozen M, Yargic ZA, Vandenplas Y. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert opinion on biological therapy. 2012 Apr 1;12(4):395-410.
13. Billoo AG, Memon MA, Khaskheli SA, Murtaza G, Iqbal K, Shekhani MS, Siddiqi AQ. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World journal of gastroenterology: WJG. 2006 Jul 28;12(28):4557.
14. Villarruel G, Rubio DM, Lopez F, Cintioni J, Gurevech R, Romero G, Vandenplas Y. Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo‚Äźcontrolled study. Acta Paediatrica. 2007 Apr 1;96(4):538-41.
15. Das S, Gupta PK, Das RR. Efficacy and safety of saccharomyces boulardii in acute rotavirus diarrhea: double blind randomized controlled trial from a developing country. Journal of tropical pediatrics. 2016 Jun 9;62(6):464-70